Fused furans for the treatment of hepatitis C
US-9738653-B2 · Aug 22, 2017 · US
Furopyridine compounds for the treatment of hepatitis C
US9957278B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9957278-B2 |
| Application number | US-201515500110-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 4, 2015 |
| Priority date | Aug 5, 2014 |
| Publication date | May 1, 2018 |
| Grant date | May 1, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Compounds of formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
First claim
Opening claim text (preview).
We claim: 1. A compound of the formula Structure
Assignees
Inventors
Classifications
Heterocyclic compounds · CPC title
Isotopically modified compounds, e.g. labelled · CPC title
- C07D491/048Primary
the oxygen-containing ring being five-membered · CPC title
for RNA viruses · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9957278B2 cover?
- Compounds of formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
- Who is the assignee on this patent?
- Bristol Myers Squibb Co
- What technology area does this patent fall under?
- Primary CPC classification C07D491/048. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue May 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).